CG-SpikeDown / Caregen - LARVOL DELTA

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Caregen Co. Ltd. | Phase classification: P1/2 ➔ P1 | N=60 ➔ 16 | Trial completion date: May 2023 ➔ Jan 2023 | Initiation date: May 2022 ➔ Oct 2022 | Trial primary completion date: May 2022 ➔ Jan 2023

Enrollment change • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date